Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients

Medical University of Gdansk

Status: Enrolling

Conditions: Thrombosis; Critical Illness

Treatments: Diagnostic Test: Serum anti-Xa activity

Study type: Observational

Funder types: Other

Identifiers

NCT06055907

SKN+JS

Details and patient eligibility

About

Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Circulatory failure
• Supported by continuous infusion of noradrenaline or noradrenaline and argipressin
• Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.

Exclusion criteria

• Contraindications for dalteparin
• Severe coagulopathy
• Acute or subacute bacterial endocarditis
• Pregnant women
• BMI (body mass index) > 30kg/m2
• Chronic kidney disease with eGFR (estimated glomerular filtration rate) < 30 ml/min/1.73 m2
• Renal replacement therapy
• The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin

Trial design

50 participants in 2 patient groups

NOR+ARG

Description:

Critically ill patients receiving norepinephrine and argipressin, with antithrombotic prophylaxis with 5000 IU of dalteparin.

Treatment:

Diagnostic Test: Serum anti-Xa activity

NOR

Description:

Critically ill patients receiving norepinephrine alone, with antithrombotic prophylaxis with 5000 IU of dalteparin.

Treatment:

Diagnostic Test: Serum anti-Xa activity